B. Gourdet et al. / Tetrahedron 66 (2010) 6026e6031
6029
inseparable mixture of the enamide 2b and the imide 3a as a pale
orange oil (119 mg, 75%, adjusted yield of 2b).
(2ꢁCH), 126.0 (CH), 122.5 (CH), 62.2 (CH2), 46.9 (CH2), 34.2 (CH2),
31.5 (CH2); HRMS (ES) exact mass calcd for C19H23N2O2 [MþNH4]þ:
311.1754, found: 311.1748.
Data for 2b: Rf¼0.72 (60% EtOAc/hexane); IR (film) 2929, 2857,
1747 (C]O), 1654, 1470, 1300, 1248, 1037, 733 cmꢂ1 1H NMR
;
(360 MHz, CDCl3)
d
7.26 (2H, d, J¼8.8 Hz, ArH), 6.85 (2H, d, J¼8.8 Hz,
4.2.1.6. 3-[(E)-2-(4-Acetylphenyl)-4-phenylbut-1-enyl]ox-
azolidin-2-one (2f). The title compound was prepared according to
general procedure using ynamide 1b (86 mg, 0.40 mmol) and 4-
acetylphenylboronic acid (131 mg, 0.80 mmol) and purified by
column chromatography (12% EtOAc/hexane/25% EtOAc/hexane)
to give an orange solid (81 mg, 60%). Rf ¼ 0.47 (60% EtOAc/hexane);
mp 116e118 ꢀC; IR (CHCl3) 2985, 2920, 1759 (C]O), 1679 (C]O),
ArH), 6.50 (1H, s, ]CH), 4.42 (2H, app dd, J¼8.9, 7.0 Hz, CH2O), 4.08
(2H, app dd, J¼8.9, 7.0 Hz, CH2N), 3.81 (3H, s, OCH3), 3.60 (2H, t,
J¼6.5 Hz, CH2OSi), 2.79 (2H, t, J¼6.5 Hz, ]CCH2), 0.84 (9H, s, SiC
(CH3)3), ꢂ0.05 (6H, s, Si(CH3)2); 13C NMR (62.9 MHz, CDCl3)
d 158.9
(C), 157.4 (C), 132.7 (C), 127.9 (2ꢁCH), 126.9 (C), 122.6 (CH), 113.7
(2ꢁCH), 62.4 (CH2), 61.1 (CH2), 55.2 (CH3), 46.4 (CH2), 32.8 (CH2),
25.8 (3ꢁCH3), 18.2 (C), ꢂ5.5 (2ꢁCH3); HRMS (ES) exact mass calcd
for C20H32NO4Si [MþH]þ: 378.2095, found: 378.2103.
1479, 1404, 1212, 1087, 910, 731 cmꢂ1
;
1H NMR (500 MHz, CDCl3)
d
7.97e7.95 (2H, m, ArH), 7.50e7.48 (2H, m, ArH), 7.30e7.27 (2H, m,
ArH), 7.22e7.18 (1H, m, ArH), 7.13e7.11 (2H, m, ArH), 6.56 (1H, s, ]
CH), 4.34e4.31 (2H, m, CH2O), 3.66e3.63 (2H, m, CH2N), 2.91 (2H, t,
J¼7.6 Hz, CH2CH2Ph), 2.68 (2H, t, J¼7.6 Hz, CH2CH2Ph), 2.62 (3H, s,
4.2.1.3. 3-[(E)-4-(tert-Butyldimethylsilyloxy)-2-p-tolylbut-1-enyl]
oxazolidin-2-one (2c). The title compound was prepared according
to the general procedure using ynamide 1a (108 mg, 0.40 mmol)
and 4-tolylboronic acid (109 mg, 0.80 mmol) and purified by col-
umn chromatography (15% EtOAc/hexane/20% EtOAc/hexane) to
give a pale orange oil (89 mg, 61%). Rf¼0.81 (60% EtOAc/hexane); IR
(film) 2928, 2857, 1754 (C]O), 1654, 1481, 1297, 1257, 1042,
CH3); 13C NMR (125.8 MHz, CDCl3)
d 197.5 (C), 156.9 (C), 145.2 (C),
141.0 (C), 135.9 (C), 128.7 (2ꢁCH), 128.4 (4ꢁCH), 128.3 (C), 126.8
(2ꢁCH), 126.2 (CH), 124.3 (CH), 62.3 (CH2), 45.7 (CH2), 34.4 (CH2),
31.1 (CH2), 26.6 (CH3); HRMS (ES) exact mass calcd for C21H22NO3
[MþH]þ: 336.1594, found: 336.1592.
778 cmꢂ1
;
1H NMR (360 MHz, CDCl3)
d
7.23 (2H, d, J¼8.1 Hz, ArH),
7.13 (2H, d, J¼8.1 Hz, ArH), 6.57 (1H, s, ]CH), 4.43 (2H, app dd,
J¼8.9, 7.0 Hz, CH2O), 4.11 (2H, app dd, J¼8.9, 7.0 Hz, CH2N), 3.61 (2H,
t, J¼6.5 Hz, CH2OSi), 2.82 (2H, t, J¼6.5 Hz, ]CCH2), 2.35 (3H, s,
ArCH3), 0.85 (9H, s, SiC(CH3)3), ꢂ0.04 (6H, s, Si(CH3)2); 13C NMR
4.2.1.7. 4-{1-[1-(2-Oxooxazolidin-3-yl)meth-(E)-ylidene]-3-phe-
nylpropyl}benzoic acid ethyl ester (2g). The title compound was
prepared according to the general procedure using ynamide 1b
(86 mg, 0.40 mmol) and 4-ethoxycarbonylphenylboronic acid
(155 mg, 0.80 mmol) and purified by column chromatography (10%
EtOAc/hexane/20% EtOAc/hexane) to give a pale yellow oil
(82 mg, 56%). Rf¼0.44 (50% EtOAc/hexane); IR (film) 2982, 2926,
1759 (C]O), 1712 (C]O), 1479, 1403, 1212, 1107, 910, 756 cmꢂ1; 1H
(62.9 MHz, CDCl3)
d
157.4 (C), 137.4 (C), 136.9 (C), 129.0 (2ꢁCH),
126.7 (2ꢁCH), 126.5 (C), 123.1 (CH), 62.4 (CH2), 61.2 (CH2), 46.3
(CH2), 32.7 (CH2), 25.8 (3ꢁCH3), 21.0 (CH3), 18.2 (C), ꢂ5.5 (2ꢁCH3);
HRMS (ES) exact mass calcd for C20H32NO3Si [MþH]þ: 362.2146,
found: 362.2143.
NMR (500 MHz, CDCl3)
d
8.05 (2H, d, J¼8.5 Hz, ArH), 7.47 (2H, d,
J¼8.5 Hz, ArH), 7.30e7.27 (2H, m, ArH), 7.22e7.19 (1H, m, ArH),
7.13e7.11 (2H, m, ArH), 6.54 (1H, s, ]CH), 4.41 (2H, q, J¼7.1 Hz,
OCH2CH3), 4.35e4.32 (2H, m, OCH2CH2N), 3.66e3.63 (2H, m,
CH2N), 2.92 (2H, t, J¼7.6 Hz, CH2CH2Ph), 2.69 (2H, t, J¼7.6 Hz,
CH2CH2Ph), 1.43 (3H, t, J¼7.1 Hz, OCH2CH3); 13C NMR (125.8 MHz,
4.2.1.4. 3-[(E)-4-(tert-Butyldimethylsilyloxy)-2-(4-dibenzofur-
anyl)but-1-enyl]oxazolidin-2-one (2d). The general procedure was
followed using ynamide 1a (108 mg, 0.40 mmol) and 4-dibenzo-
furanboronic acid (169 mg, 0.80 mmol). Purification by column
chromatography (10% EtOAc/hexane/20% EtOAc/hexane) gave
a 13:1 inseparable mixture of the enamide 2d and the imide 3a as
a cream solid (84 mg, 46%, adjusted yield of 2d).
CDCl3)
d
166.3 (C), 156.9 (C), 144.9 (C), 141.1 (C), 129.8 (2ꢁCH), 129.2
(C), 128.8 (C), 128.4 (4ꢁCH), 126.6 (2ꢁCH), 126.2 (CH), 124.0 (CH),
62.3 (CH2), 60.9 (CH2), 45.7 (CH2), 34.3 (CH2), 31.2 (CH2), 14.3 (CH3);
HRMS (ES) exact mass calcd for C22H24NO4 [MþH]þ: 366.1700,
found: 366.1697.
Data for 2d: Rf¼0.49 (50% EtOAc/hexane); mp 88e91 ꢀC; IR
(CHCl3) 2954, 2928, 2857, 1759 (C]O), 1655, 1404, 1264, 1226, 1187,
1090, 837, 750, 704 cmꢂ1; 1H NMR (500 MHz, CDCl3)
d 7.96 (1H, d,
J¼7.7, ArH), 7.88 (1H, dd, J¼7.5, 1.4 Hz, ArH), 7.57 (1H, d, J¼8.2 Hz,
ArH), 7.48e7.45 (1H, m, ArH), 7.38e7.34 (2H, m, ArH), 7.31 (1H, t,
J¼7.6 Hz, ArH), 6.91 (1H, s, ]CH), 4.51e4.47 (2H, m, OCH2CH2N),
4.30e4.26 (2H, m, CH2N), 3.62 (2H, t, J¼6.4 Hz, CH2OSi), 3.11 (2H, t,
J¼6.4 Hz, ]CCH2), 0.84 (9H, s, SiC(CH3)3), ꢂ0.08 (6H, s, Si(CH3)2);
4.2.1.8. 3-[2,2-Diphenylvinyl]oxazolidin-2-one (2h). The title
compound was prepared according to the general procedure using
ynamide 1c (75 mg, 0.40 mmol) and phenylboronic acid (98 mg,
0.80 mmol) and purified by column chromatography (15% EtOAc/
hexane/20% EtOAc/hexane) to give a colorless solid (71 mg, 67%).
Rf¼0.72 (60% EtOAc/hexane); mp 90e92 ꢀC; IR (film) 2925, 2855,
13C NMR (125.8 MHz, CDCl3)
d 157.2 (C), 155.8 (C), 153.6 (C), 127.3
(CH),127.1 (CH),126.1 (CH),125.7 (C),124.4 (C),124.1 (C),122.9 (CH),
122.7 (CH), 120.9 (C), 120.6 (CH), 119.5 (CH), 111.7 (CH), 62.5 (CH2),
61.2 (CH2), 46.1 (CH2), 32.6 (CH2), 25.8 (3ꢁCH3), 18.2 (C), ꢂ5.6
(2ꢁCH3); HRMS (ES) exact mass calcd for C25H32NO4Si [MþH]þ:
438.2095, found: 438.2091.
1755 (C]O), 1685, 1444, 1265, 1213, 1042, 736 cmꢂ1 1H NMR
;
(360 MHz, CDCl3)
7.20e7.17 (2H, m, ArH), 7.15 (1H, s, ]CH), 4.22e4.18 (2H, m, CH2O),
3.16e3.12 (2H, m, CH2N); 13C NMR (62.9 MHz, CDCl3)
157.2 (C),
d 7.39e7.35 (3H, m, ArH), 7.29e7.22 (5H, m, ArH),
d
140.8 (C), 138.0 (C), 130.8 (2ꢁCH), 128.2 (4ꢁCH), 127.8 (CH), 127.0
(3ꢁCH), 126.1 (C), 122.4 (CH), 62.6 (CH2), 44.9 (CH2); HRMS (ES)
exact mass calcd for C17H16NO2 [MþH]þ: 266.1176, found: 266.1183.
4.2.1.5. 3-[(E)-2,4-Diphenylbut-1-enyl]oxazolidin-2-one (2e). The
title compound was prepared according to the general procedure
using ynamide 1b (86 mg, 0.40 mmol) and phenylboronic acid
(98 mg, 0.80 mmol) and purified by column chromatography (15%
4.2.1.9. 3-[(E)-2-(4-Chlorophenyl)-2-phenylvinyl]oxazolidin-2-
one (2i). The title compound was prepared according to the general
procedure using ynamide 1c (75 mg, 0.40 mmol) and 4-chloro-
phenylboronic acid (125 mg, 0.80 mmol) and purified by column
chromatography (15% EtOAc/hexane/20% EtOAc/hexane) to give
a pale yellow solid (79 mg, 65%). Rf¼0.57 (50% EtOAc/hexane); mp
136e138 ꢀC; IR (film) 2918, 2865, 1759 (C]O), 1637, 1405, 1262,
EtOAc/hexane/20% EtOAc/hexane) to give
(105 mg, 89%). Rf¼0.71 (60% EtOAc/hexane); IR (film) 2985, 2923,
1751 (C]O), 1480, 1405, 1221, 1087, 908, 734 cmꢂ1 1H NMR
(360 MHz, CDCl3) 7.32e7.25 (4H, m, ArH), 7.23e7.15 (3H, m, ArH),
a pale brown oil
;
d
7.11e7.03 (3H, m, ArH), 6.28 (1H, s, ]CH), 4.21e4.17 (2H, m, CH2O),
3.49e3.45 (2H, m, CH2N), 2.78 (2H, t, J¼7.6 Hz, CH2CH2Ph), 2.58 (2H,
1211, 1039, 744 cmꢂ1 1H NMR (360 MHz, CDCl3)
; d 7.39e7.37 (3H,
t, J¼7.6 Hz, CH2CH2Ph); 13C NMR (62.9 MHz, CDCl3)
d
157.0 (C), 141.4
m, ArH), 7.24e7.22 (4H, m, ArH), 7.14e7.10 (3H, m, ArH and ]CH),
(C), 140.0 (C),131.3 (C), 128.5 (4ꢁCH), 128.3 (2ꢁCH), 127.4 (CH), 126.8
4.21 (2H, app t, J¼7.9 Hz, CH2O), 3.14 (2H, app t, J¼7.9 Hz, CH2N); 13
C